Valuation: MannKind Corporation

Capitalization 995M 856M 783M 747M 1.37B 95.44B 1.39B 9.39B 3.63B 45.31B 3.73B 3.65B 158B P/E ratio 2026 *
-40.3x
P/E ratio 2027 * 23.4x
Enterprise value 995M 856M 783M 747M 1.37B 95.44B 1.39B 9.39B 3.63B 45.31B 3.73B 3.65B 158B EV / Sales 2026 *
2.17x
EV / Sales 2027 * 1.92x
Free-Float
98.44%
Yield 2026 *
-
Yield 2027 * -
1 day-3.88%
1 week-12.36%
Current month+9.01%
1 month+11.37%
3 months-44.31%
6 months-38.05%
Current year-45.59%
1 week 3.07
Extreme 3.07
3.6
1 month 2.59
Extreme 2.59
4.29
Current year 2.23
Extreme 2.23
6.51
1 year 2.23
Extreme 2.23
6.51
3 years 2.23
Extreme 2.23
7.63
5 years 2.23
Extreme 2.23
7.63
10 years 0.67
Extreme 0.6662
7.63
Manager TitleAgeSince
Chief Executive Officer 49 2017-05-24
Director of Finance/CFO 51 2024-04-21
Chief Tech/Sci/R&D Officer - 2025-09-28
Director TitleAgeSince
Director/Board Member 82 2003-09-30
Director/Board Member 82 2003-11-30
Chairman 69 2020-12-08
Change 5d. change 1-year change 3-years change Capi.($)
-3.88%-12.36%-32.35%-31.90% 995M
-0.14%+3.34%+42.69%+84.71% 50.39B
+0.12%-7.32%+68.98%+55.74% 46.03B
-4.96%+7.60%+62.23%+465.91% 25.06B
-3.05%-5.22%-3.39%-17.32% 23.26B
+3.19%+1.20%+41.51%-26.86% 17.24B
-1.66%-4.24%+29.99%-41.30% 16.15B
-2.91%-12.84%+46.76%+182.49% 14.56B
-5.65%-5.64%-26.11%+832.30% 14.08B
+0.41%-4.04%+39.40% - 12.94B
Average -1.84%-1.77%+26.97%+167.08% 22.07B
Weighted average by Cap. -1.29%-0.37%+39.86%+150.74%

Financials

2026 *2027 *
Net sales 459M 395M 361M 345M 632M 44.08B 643M 4.34B 1.68B 20.92B 1.72B 1.69B 72.9B 518M 446M 407M 389M 713M 49.69B 724M 4.89B 1.89B 23.59B 1.94B 1.9B 82.18B
Net income -14.25M -12.26M -11.21M -10.7M -19.61M -1.37B -19.94M -135M -52.06M -649M -53.48M -52.34M -2.26B 55.14M 47.44M 43.38M 41.39M 75.88M 5.29B 77.13M 520M 201M 2.51B 207M 202M 8.75B
Net Debt - -
Logo MannKind Corporation
MannKind Corporation is a biopharmaceutical company engaged in transforming chronic disease care through patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, it develops and commercializes treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease. Its commercial assets include Afrezza, FUROSCIX and V-Go along with Tyvaso DPI. Its commercializing Afrezza (insulin human) Inhalation Powder, an ultra-rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes, and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin. Its orphan lung disease product, Tyvaso DPI (treprostinil) inhalation powder, is used in the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).
Employees
592
Date Price Change Volume
26-05-15 3.083 $ -4.26% 2,221,251
26-05-14 3.220 $ +0.31% 3,592,242
26-05-13 3.210 $ -2.13% 4,510,656
26-05-12 3.280 $ -2.38% 5,514,111
26-05-11 3.360 $ -4.55% 7,537,876
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
3.220USD
Average target price
7.469USD
Spread / Average Target
+131.95%

Quarterly revenue - Rate of surprise